Immediate Impact

57 standout
Sub-graph 1 of 24

Citing Papers

The present and future of bispecific antibodies for cancer therapy
2024 Standout
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial
2024 Standout
4 intermediate papers

Works of Xinqun Yang being referenced

Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer
2010
An Open-Label Clinical Trial Evaluating Safety and Pharmacokinetics of Two Dosing Schedules of Panitumumab in Patients with Solid Tumors
2009

Author Peers

Author Last Decade Papers Cites
Xinqun Yang 253 113 47 170 7 399
Stephen Eppler 183 37 46 140 9 392
Maksim Yezhelyev 242 49 55 172 6 417
Colvin Om 170 190 52 83 11 425
Steven King 285 54 29 114 7 457
Giovanni Pacchiana 259 34 37 96 7 357
Sanaa T. Dergham 174 95 45 314 11 450
LA Falk 273 111 21 97 8 421
G�nther Gastl 207 36 94 111 8 432
LR Ellingsworth 225 242 39 95 8 429
Francis Lopez 152 94 30 123 11 392

All Works

Loading papers...

Rankless by CCL
2026